Thomas Duhen
- Immunology top 1%
- Immune Cell Function and Interaction 16
- Immunotherapy and Immune Responses 16
- T-cell and B-cell Immunology 15
- IL-33, ST2, and ILC Pathways 3
- Psoriasis: Treatment and Pathogenesis 3
- interferon and immune responses 2
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers 11
- CAR-T cell therapy research 7
- Dermatology top 2%
- Immunology and Allergy top 5%
- Physiology top 5%
- Co-authors
- Antonio LanzavecchiaFederica SallustoDavid JarrossayDaniel CampbellRebekka DuhenAndrew D. WeinbergNoel F.C.C. de MirandaBernard A. Fox
- Cited by
- ImmunologyOncologyDermatology
- Partner nations
- United StatesFranceNetherlands
In The Last Decade
Thomas Duhen
33 papers receiving 2.8k citations
Hit Papers
Peers
Comparison fields: 5 of 97
- Immunology 2.3k
- Oncology 931
- Dermatology 280
- Immunology and Allergy 89
- Physiology 57
Countries citing papers authored by Thomas Duhen
This map shows the geographic impact of Thomas Duhen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Duhen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Duhen more than expected).
Fields of papers citing papers by Thomas Duhen
This network shows the impact of papers produced by Thomas Duhen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Duhen. The network helps show where Thomas Duhen may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Thomas Duhen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 5 | |
| 2 | 2023 | 7 | |
| 3 | 2023 | 8 | |
| 4 | 2023 | 21 | |
| 5 | 2022 | 45 | |
| 6 | 2022 | 4 | |
| 7 | 2022 | 3 | |
| 8 | 2021 | 7 | |
| 9 | 2021 | 8 | |
| 10 | 2020 | 33 | |
| 11 | 2019 | 21 | |
| 12 | 2019 | 47 | |
| 13 | Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumorsbreakdown → | 2018 | 564 |
| 14 | 2017 | 52 | |
| 15 | 2014 | 3 | |
| 16 | Human CCR6+CXCR3+ "Th1/17" cells are polyfunctional and can develop from Th17 cells under the influence of IL-1{beta} and IL-12 (P4122) | 2013 | 1 |
| 17 | 2010 | 11 | |
| 18 | 2009 | 162 | |
| 19 | 2004 | 47 | |
| 20 | 1998 | 0 |
About Thomas Duhen
Thomas Duhen is a scholar working on Immunology, Oncology and Otorhinolaryngology, having authored 34 papers that have together received 2.9k indexed citations. Recurring topics across this work include Immune Cell Function and Interaction (16 papers), Immunotherapy and Immune Responses (16 papers), T-cell and B-cell Immunology (15 papers), Cancer Immunotherapy and Biomarkers (11 papers), CAR-T cell therapy research (7 papers), IL-33, ST2, and ILC Pathways (3 papers), Psoriasis: Treatment and Pathogenesis (3 papers) and interferon and immune responses (2 papers). The work is most often cited by research in Immunology (2.3k citations), Oncology (931 citations) and Dermatology (280 citations). Thomas Duhen has collaborated with scholars based in United States, France and Netherlands. Frequent co-authors include Antonio Lanzavecchia, Federica Sallusto, David Jarrossay, Daniel Campbell, Rebekka Duhen, Andrew D. Weinberg, Noel F.C.C. de Miranda, Bernard A. Fox, Nathalie Bendriss‐Vermare and Rom S. Leidner. Their work appears in journals such as The Journal of Immunology, Blood, Nature Communications, Journal of Clinical Oncology and Journal for ImmunoTherapy of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.